New company Tarsa set up around Unigene's Phase III oral calcitonin programme
This article was originally published in Scrip
Executive Summary
Unigene has joined with a syndicate of venture capital firms to establish a new company focused on the development of its Phase III oral calcitonin programme for the treatment of osteoporosis.